# Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients

> **NCT00271323** · PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 14 (actual)

## Conditions studied

- Non-Small-Cell Lung Carcinoma

## Interventions

- **DRUG:** docetaxel and cisplatin
- **RADIATION:** radiotherapy

## Key facts

- **NCT ID:** NCT00271323
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-05
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2009-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00271323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00271323, "Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT00271323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*